logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Prostate cancer: ultra-hypofractionation noninferior to conventional radiotherapy

Phase 3 HYPO-RT-PC trial reported similar 5-year adverse effect profile.